BioCryst Shareholders Sue Over Idera Merger Plan
BioCryst Pharmaceuticals Inc. and its board of directors have undervalued the biotechnology company by agreeing to a "merger of equals" with Idera Pharmaceuticals Inc., a shareholder says in a proposed class...To view the full article, register now.
Already a subscriber? Click here to view full article